CytRx Drug Candidate INNO-206 Results In Ovarian Tumor Shrinkage in Animal Trials

LOS ANGELES -- CytRx Corporation, a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that results demonstrating that its cancer drug candidate INNO-206 caused statistically significant tumor shrinkage in an animal model of ovarian cancer have been accepted for publication in the peer-reviewed journal Investigational New Drugs. The manuscript based on this animal trial, "INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model," was made available ahead of journal printing in electronic format...